Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2018

01-03-2018 | Original Article

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Authors: Xu-chao Zhang, Xu Cao, Chun Sun, Zhi Xie, Jian-jun Guo, Jin-ji Yang, Xue-ning Yang, Hang-jun Dai, Su-chun Li, Xin-ran Xu, Yun-xia Zuo, Meng Chen, Hartmut Koeppen, Jing He, Astrid Kiermaier, David Shames, Gang Cheng, Yi-long Wu

Published in: Cancer Immunology, Immunotherapy | Issue 3/2018

Login to get access

Abstract

The goal of this study is to evaluate PD-L1 prevalence and its association with major clinical characteristics in Chinese non-small cell lung cancer (NSCLC) patients to inform the clinical development of anti-PD1/PD-L1 agents in this population. We used phosphatase and tensin homolog (PTEN) expression through IHC as a surrogate tissue quality marker to screen surgical NSCLC samples in tissue microarray (TMA; 172 cases) or whole-section (268 cases) format. The samples were then analyzed with a clinically validated PD-L1 IHC assay. The results were correlated with baseline characteristics and clinical outcomes. PTEN IHC showed that 108 TMA samples and 105 whole-section samples qualified for PD-L1 IHC. With a clinically relevant cutoff, 41.7% of the TMA samples were PD-L1 positive. PD-L1 level was much lower in EGFR-mutant patients and seemed to be a favorable prognostic factor for both overall survival (OS) and recurrence-free survival (RFS). These findings were confirmed in the whole-section samples except that their survival data were not mature enough for correlation analysis. In summary, PD-L1 expression was detected in approximately 40% of PTEN-qualified Chinese NSCLC samples, negatively correlated with EGFR mutation and seemed to be a favorable prognostic factor for both OS and RFS. Notably, the different results from PTEN-qualified and PTEN-disqualified samples underscore the importance of tissue quality control prior to biomarker testing.
Appendix
Available only for authorised users
Literature
1.
Zhang X-c, Cao X, Sun C, Xie Z, Guo J-j, Yang J-j et al. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening. In ESMO Asia. 2016. Singapore. Ann Oncol 27(suppl_9):ix9–ix18. https://​doi.​org/​10.​1093/​annonc/​mdw574
2.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. GLOBOCAN 2012 v1.0. 2012. http://​globocan.​iarc.​fr. Accessed 31 Mar 2017
3.
4.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefPubMed
5.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594CrossRefPubMedPubMedCentral
6.
Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28(36):5311–5320CrossRefPubMed
7.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al (2011) International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285CrossRefPubMedPubMedCentral
8.
Cetin K, Ettinger DS, Hei YJ, O’Malley CD (2011) Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 3:139–148CrossRefPubMedPubMedCentral
9.
Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality? Nat Rev Clin Oncol 7(7):401–414CrossRefPubMed
10.
Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8(11):661–668CrossRefPubMed
11.
Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R et al (2011) Treatment of advanced non small cell lung cancer. J Thorac Dis 3(2):122–133PubMedPubMedCentral
12.
Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K (2012) Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 23(6):1537–1541CrossRefPubMed
13.
Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18(24):6580–6587CrossRefPubMed
14.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846CrossRefPubMed
15.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRefPubMedPubMedCentral
16.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422CrossRefPubMed
17.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704CrossRefPubMed
18.
19.
20.
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550CrossRefPubMed
21.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMedPubMedCentral
22.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833CrossRefPubMed
23.
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10CrossRefPubMed
24.
Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–477CrossRefPubMed
25.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265CrossRefPubMed
26.
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111–122CrossRefPubMedPubMedCentral
27.
Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X et al (2011) The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 187(3):1113–1119CrossRefPubMedPubMedCentral
28.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356–362CrossRefPubMed
29.
Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD et al (2010) Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18(4):371–374CrossRefPubMedPubMedCentral
30.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567CrossRefPubMedPubMedCentral
31.
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12(2):208–222CrossRefPubMed
32.
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB et al (2017) A prospective multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 3(8):1051–1058CrossRefPubMedPubMedCentral
33.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128CrossRefPubMedPubMedCentral
34.
Zhang J, Ou JX, Bai CX (2011) Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology 16(8):1165–1172CrossRefPubMed
35.
Zheng R, Zeng H, Zuo T, Zhang S, Qiao Y, Zhou Q et al (2016) Lung cancer incidence and mortality in China, 2011. Thorac Cancer 7(1):94–99CrossRefPubMed
36.
Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z et al (2016) Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11(7):1003–1011CrossRefPubMed
37.
Pan ZK, Ye F, Wu X, An HX, Wu JX (2015) Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 7(3):462–470PubMedPubMedCentral
38.
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY et al (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 41(4):450–456CrossRefPubMed
39.
D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L et al (2015) PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112(1):95–102CrossRefPubMed
40.
Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M et al (2015) PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2):181–188CrossRefPubMed
41.
Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T et al (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940CrossRefPubMed
42.
Lin K, Cheng J, Yang T, Li Y, Zhu B (2015) EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB. Biochem Biophys Res Commun 463(1–2):95–101CrossRefPubMed
43.
Song Z, Yu X, Cheng G, Zhang Y (2016) Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med 14(1):188CrossRefPubMedPubMedCentral
44.
Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y et al (2015) The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6(16):14209–14219CrossRefPubMedPubMedCentral
45.
Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H et al (2016) Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with Immune Microenvironment. J Thorac Oncol 11(11):1869–1878CrossRefPubMed
46.
Inamura K, Yokouchi Y, Sakakibara R, Kobayashi M, Subat S, Ninomiya H et al (2016) Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol 46(10):935–941CrossRefPubMed
47.
Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W et al (2016) PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 17(4):407–413CrossRefPubMedPubMedCentral
48.
Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM et al (2015) Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 28(9):1154–1166CrossRefPubMed
49.
Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK (2016) PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer 93:9–16CrossRefPubMed
50.
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S et al (2016) Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol 11(11):1879–1890CrossRefPubMed
51.
Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H et al (2014) Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 7:567–573CrossRefPubMedPubMedCentral
52.
Zhou ZJ, Zhan P, Song Y (2015) PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 4(2):203–208CrossRefPubMedPubMedCentral
53.
Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K et al (2016) PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol 9(1):64–69CrossRefPubMedPubMedCentral
54.
Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S et al (2016) PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PLoS One 11(4):e0153954CrossRefPubMedPubMedCentral
55.
Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T et al (2015) Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 10(3):426–430CrossRefPubMed
56.
Lin C, Chen X, Li M, Liu J, Qi X, Yang W et al (2015) Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer 16(5):e25–e35CrossRefPubMed
57.
Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L et al (2017) PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget 8(33):53978–53988CrossRefPubMedPubMedCentral
58.
Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH et al (2015) PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 10(8):e0136023CrossRefPubMedPubMedCentral
59.
Toyokawa G, Takada K, Haratake N, Takamori S, Akamine T, Katsura M et al (2016) Favorable disease-free survival associated with programmed death ligand 1 expression in patients with surgically resected small-cell lung cancer. Anticancer Res 36(8):4329–4336PubMed
60.
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2016) Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 57:91–103CrossRefPubMed
Metadata
Title
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening
Authors
Xu-chao Zhang
Xu Cao
Chun Sun
Zhi Xie
Jian-jun Guo
Jin-ji Yang
Xue-ning Yang
Hang-jun Dai
Su-chun Li
Xin-ran Xu
Yun-xia Zuo
Meng Chen
Hartmut Koeppen
Jing He
Astrid Kiermaier
David Shames
Gang Cheng
Yi-long Wu
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2098-4

Other articles of this Issue 3/2018

Cancer Immunology, Immunotherapy 3/2018 Go to the issue

Original Article

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgements

Review

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Original Article

Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737

Original Article

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Original Article

Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits